Edit Module

Drug to Treat Canine Lymphoma Gets FDA Approval

Tanovea-CA1, from veterinary cancer therapeutics company VetDC, is expected available to veterinarians in spring 2017.


Published:

VetDC, Inc., a veterinary cancer therapeutics company, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has granted a conditional approval of Tanovea™-CA1 (rabacfosadine for injection) for the treatment of lymphoma in dogs.

“This is a significant milestone for VetDC, and we are excited to announce the first ever FDA-approved drug for canine lymphoma,” stated Steven Roy, VetDC’s president and CEO. “We look forward to introducing Tanovea-CA1 to the veterinary cancer community in the months to come.”

Tanovea-CA1 is expected to be available to veterinarians in the spring of 2017, Roy added.

“The conditional approval of Tanovea-CA1 represents a first on multiple levels for veterinary oncology, and we eagerly anticipate adding this very active and promising new drug to our lymphoma fighting arsenal,” noted Dr. Philip J. Bergman, a board-certified veterinary oncologist at VCA-Katonah Bedford Veterinary Center in Bedford Hills, N.Y.

For more information about Tanovea-CA1 and VetDC, visit the Tanovea website or VetDC website.

Edit Module
Edit ModuleShow Tags

Archive »Read More

The Latest in Treating Canine Lymphoma

Chemotherapy, antibody therapy and immunotherapy continue to provide hope.

The Gonadectomy Controversy

Exploring the available data, making the case for more information and weighing the risks with pet owners.

Is it a Medical Problem or a Behavior Problem?

Manage tricky behavior cases by determining medical factors, championing client education and knowing when to refer issues beyond your clinic’s scope.
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module